Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Erlotinib may stop
the growth of tumor cells by blocking some of the enzymes needed for cell growth and by
blocking blood flow to the tumor. It may also make tumor cells more sensitive to radiation
therapy. Giving radiation therapy together with erlotinib may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of erlotinib when
given together with radiation therapy and to see how well they work in treating young
patients with newly diagnosed glioma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
St. Jude Children's Research Hospital
Collaborators:
Duke University Rady Children's Hospital, San Diego